EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Ceftazidime/avibactam and eravacycline susceptibility of carbapenem-resistant Klebsiella pneumoniae in two Greek tertiary teaching hospitals

Maria Chatzidimitriou, Panagiota Chatzivasileiou, Georgios Sakellariou, MariaAnna Kyriazidi, Asimoula Kavvada, Dimitris Chatzidimitriou, Fani Chatzopoulou, Georgios Meletis, Maria Mavridou, Dimitris Rousis, Eleni Katsifa, Eleni Vagdatli, Stella Mitka, Lialiaris Theodoros

Acta Microbiologica et Immunologica Hungarica · 2021-06-21 · 68 (2) · 65-72

DOI: 10.1556/030.2021.01364 ↗
AbstractBibliografische Angaben

Abstract

Abstract The present study evaluated the carbapenem resistance mechanisms of Klebsiella pneumoniae strains isolated in two Greek tertiary teaching hospitals and their susceptibility to currently used and novel antimicrobial agents. Forty-seven carbapenem resistant K. pneumoniae strains were collected in G. Papanikolaou and Ippokrateio hospital of Thessaloniki between 2016 and 2018. Strain identification and antimicrobial susceptibility was conducted by Vitek 2 system (Biomérieux France). Susceptibility against new antimicrobial agents was examined by disk diffusion method. Polymerase chain reaction (PCR) was used to detect bla KPC , bla VIM , bla NDM and bla OXA-48 genes. The meropenem–EDTA and meropenem–boronic acid synergy test performed on the 24 K. pneumoniae strains demonstrated that 8 (33.3%) yielded positive for metallo-beta-lactamases (MBL) and 16 (66.6%) for K. pneumonia carbapenemases (KPC) production. Colistin demonstrated the highest in vitro activity (87.7%) among the 47 K. pneumoniae strains followed by gentamicin (76.5%) and tigecycline (51%). Among new antibiotics ceftazidime/avibactam showed the highest sensitivity (76.6%) in all strains followed by eravacycline (66.6%). The bla KPC gene was present in 30 strains (63.8%), the bla NDM in 11 (23.4%) and the bla VIM in 6 (12.8%). The bla OXA-48 gene was not detected. Well established antimicrobial agents such as colistin, gentamicin and tigecycline and novel antibiotics like ceftazidime/avibactam and eravacycline can be reliable options for the treatment of invasive infections caused by carbapenem-resistant K. pneumoniae .

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →